Vertex says Casgevy benefit extends to nearly five years in sickle cell disease [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Currently boasting the only approved CRISPR-based gene editing therapy, Vertex presented the results from the long-term follow-up trials at the annual European Haematology Association (EHA) Congress, held in Madrid, Spain from 13 to 16 June. The data is from more than 100 patients – 46 with sickle cell disease and 56 with TDT – treated with Casgevy. Casgevy was approved by the US Food and Drug Administration (FDA) in December 2023 alongside bluebird bio's Lyfgenia (lovo-cel). This was followed by a European approval in February 2024. While gene therapies have the potential to transform the treatment of rare diseases, questions remain over long-term effectiveness and safety The longer-term data from Vertex's CLIMB trials could go some way to quell any circling over Casgevy. In sickle cell disease, 92.3% of patients with at least 16 months of follow-up were free from vaso-occlusive crises (VOCs) for at least 12 consecutive months, consolidating previously reported primary endpo
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions [Yahoo! Finance]Yahoo! Finance
- Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific SessionsBusiness Wire
- Global Cystic Fibrosis Market Report 2024: Growth Amid Rising Prevalence and Innovative Therapeutic Developments - Forecasts to 2029 [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals (NASDAQ:VRTX): The Best Healthcare Stock to Buy in 2024? [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 5/6/24 - Beat
VRTX
Sec Filings
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- 6/12/24 - Form 144
- VRTX's page on the SEC website